The FDA has given tentative approval for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) investigational drug for the treatment of Indolent B-cell non-Hodgkin lymphoma.Eagle Pharmaceuticals Inc (NASDAQ:EGRX) net profit margin is -72.20% and weekly performance is 9.95%. On last trading day company shares ended up $14.25. Analysts mean target price for the company is $22.00. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) distance from 50-day simple moving average is 27.56%.
On May 19, 2014 Sophiris Bio Inc (NASDAQ:SPHS), a biopharmaceutical company developing treatments for urologic diseases, announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company intends to use the initial proceeds to support a proof of concept study of PRX302 as a treatment for localized prostate cancer. Aspire Capital has completed an initial purchase of 604,320 common shares at $3.31 per share for proceeds of $2 million and has committed to purchase up to $13 million in additional shares over the next 30 months at prices based on market price at the time of each sale, subject to a Sophiris registration statement being declared effective by the Securities and Exchange Commission (“SEC”). Sophiris Bio Inc (NASDAQ:SPHS) shares advanced 15.18% in last trading session and ended the day on $2.58. SPHS Gross its return on assets is -49.10%. Sophiris Bio Inc (NASDAQ:SPHS) quarterly performance is -25.86%.
Agile Therapeutics’ (NASDAQ:AGRX) quiet period is set to expire on Wednesday, July 2nd. Agile Therapeutics had issued 9,166,667 shares in its initial public offering on May 23rd. The total size of the offering was $55,000,002 based on an initial share price of $6.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission.Agile Therapeutics Inc (NASDAQ:AGRX) shares moved down -1.12% in last trading session and was closed at $8.79, while trading in range of $8.62-$9.50. Agile Therapeutics Inc (NASDAQ:AGRX) year to date performance is 58.66%.
On June 6,2014 In an exclusive interview with Benzinga, Evoke Pharma (NASDAQ: EVOK) CEO Dave Gonyer discussed the company’s opportunities. Evoke is currently focused on its drug EVK-001. EVK-001 is a nasal spray to treat diabetic gastroparesis.Evoke Pharma Inc (NASDAQ:EVOK) ended the last trading day at $8.00. Company weekly volatility is calculated as 6.07% and price to cash ratio as 2.24. Evoke Pharma Inc (NASDAQ:EVOK) showed a negative weekly performance of -0.87%.